Synthetic transcription factors designed by domain recombination enhance CAR T cell antitumor function
Cell · 2026-09 · 189 (19) · 6024-6043.e10
DOI: 10.1016/j.cell.2026.07.054 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell, 2026-09. Verfasst von Oliver Takacsi-Nagy und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Stanford University, Stanford, CA, USA; Center for Immunotherapy Design, Stanford University, Stanford, CA, USA; Program in …. Hauptthemen laut MEDLINE: T-Lymphocytes, Transcription Factors, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NCI NIH HHS, Mark Foundation For Cancer Research.
Abstract (Originalsprache)
Human protein-coding genes evolved via rearrangement of domains from ancestral genes. We develop a scalable, evolutionarily guided method to assemble novel genes from constituent domains within a protein family, termed DESynR (domain engineered via synthesis and recombination) genes. In primary human T cells, DESynR activator protein-1 (AP-1) transcription factors (TFs) significantly outperform natural AP-1 TFs across in vitro and in vivo antitumor assays. DESynR AP-1 TFs induce broad transcriptional and epigenetic reprogramming and establish non-natural T cell states that optimize features of exhaustion, effector and cytotoxic function, and persistence-sometimes co-opting gene modules from disparate cell types. Reprogramming is primarily driven by differential regulation of established AP-1-bound regulatory elements rather than unique binding. Finally, we screen DESynR erythroblast transformation-specific (ETS) and forkhead box (FOX) TFs to support generalizability across protein families. Overall, we demonstrate that reconfiguring existing protein domains may uncover non-evolved genes that program therapeutically relevant cell states.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Stanford University, Stanford, CA, USA; Center for Immunotherapy Design, Stanford University, Stanford, CA, USA; Program in Immunology, Stanford University, Stanford, CA, USA.
- Center for Immunotherapy Design, Stanford University, Stanford, CA, USA; Division of Allergy, Immunology, and Rheumatology, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.
- Department of Pathology, Stanford University, Stanford, CA, USA; Center for Immunotherapy Design, Stanford University, Stanford, CA, USA; Department of Genetics, Stanford University, Stanford, CA, USA.
- Department of Pathology, Stanford University, Stanford, CA, USA; Center for Immunotherapy Design, Stanford University, Stanford, CA, USA.
- Department of Pathology, Stanford University, Stanford, CA, USA; Center for Immunotherapy Design, Stanford University, Stanford, CA, USA; Department of Bioengineering, Stanford University, Stanford, CA, USA.
- Program in Immunology, Stanford University, Stanford, CA, USA; Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA; Department of Pediatrics, Stanford University School of Medicine, Stanfor…
Förderung
- NIH HHS
- NCI NIH HHS
- Mark Foundation For Cancer Research
- University of California, San Francisco
- Lupus Foundation of America
- Burroughs Wellcome Fund
- National Institutes of Health
- Stanford Maternal and Child Health Research Institute
Zitieren
APA
Takacsi-Nagy, O., Kasinathan, S., Hartman, A., Yin, Y., Wu, L., Chen, A. Y., Moser, L. M., May, A. P., Reeder, G. C., Celallos Fuentes, E., Kernick, C., Lu, J., McClellan, A. K., Raposo, C. J., Terrall, B., Theberath, N. E., Yan, P. K., Xu, P., Sotillo, E., …, & Satpathy, A. T. (2026). Synthetic transcription factors designed by domain recombination enhance CAR T cell antitumor function. Cell, 189(19), 6024-6043.e10. https://doi.org/10.1016/j.cell.2026.07.054
Vancouver
Takacsi-Nagy O, Kasinathan S, Hartman A, Yin Y, Wu L, Chen AY, et al. Synthetic transcription factors designed by domain recombination enhance CAR T cell antitumor function. Cell. 2026;189(19):6024-6043.e10. doi:10.1016/j.cell.2026.07.054
BibTeX
@article{TakacsiNagy2026,
author = {Takacsi-Nagy, Oliver and Kasinathan, Sivakanthan and Hartman, Austin and Yin, Yajie and Wu, Lujing and Chen, Andy Y and Moser, Laura M and May, Audre P and Reeder, Gabriella C and Celallos Fuentes, Emily and Kernick, Courtney and Lu, Johnathan and McClellan, Alison K and Raposo, Colin J and Terrall, Brendan and Theberath, Nicole E and Yan, Patrick K and Xu, Peng and Sotillo, Elena and Eyquem, Justin and Mackall, Crystal L and Roth, Theodore L and Satpathy, Ansuman T},
title = {Synthetic transcription factors designed by domain recombination enhance CAR T cell antitumor function},
journal = {Cell},
year = {2026},
volume = {189},
number = {19},
pages = {6024--6043.e10},
doi = {10.1016/j.cell.2026.07.054}
}
EUVIMED